JP2023514056A - 免疫調節を使用した癌の治療レジメン - Google Patents

免疫調節を使用した癌の治療レジメン Download PDF

Info

Publication number
JP2023514056A
JP2023514056A JP2022544294A JP2022544294A JP2023514056A JP 2023514056 A JP2023514056 A JP 2023514056A JP 2022544294 A JP2022544294 A JP 2022544294A JP 2022544294 A JP2022544294 A JP 2022544294A JP 2023514056 A JP2023514056 A JP 2023514056A
Authority
JP
Japan
Prior art keywords
talabostat
dose
patients
months
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514056A5 (https=
Inventor
ジェイ． オニール，ヴィンセント
Original Assignee
バイオエクセル セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエクセル セラピューティクス，インコーポレイテッド filed Critical バイオエクセル セラピューティクス，インコーポレイテッド
Publication of JP2023514056A publication Critical patent/JP2023514056A/ja
Publication of JP2023514056A5 publication Critical patent/JP2023514056A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022544294A 2020-02-07 2021-02-05 免疫調節を使用した癌の治療レジメン Pending JP2023514056A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062971548P 2020-02-07 2020-02-07
US62/971,548 2020-02-07
US202063029066P 2020-05-22 2020-05-22
US63/029,066 2020-05-22
US202063069405P 2020-08-24 2020-08-24
US63/069,405 2020-08-24
US202063088038P 2020-10-06 2020-10-06
US63/088,038 2020-10-06
US202063092039P 2020-10-15 2020-10-15
US63/092,039 2020-10-15
US202063105679P 2020-10-26 2020-10-26
US63/105,679 2020-10-26
US202063107053P 2020-10-29 2020-10-29
US63/107,053 2020-10-29
US202163139594P 2021-01-20 2021-01-20
US63/139,594 2021-01-20
PCT/US2021/016764 WO2021158884A1 (en) 2020-02-07 2021-02-05 Treatment regimen for cancer using immunomodulation

Publications (2)

Publication Number Publication Date
JP2023514056A true JP2023514056A (ja) 2023-04-05
JP2023514056A5 JP2023514056A5 (https=) 2023-12-04

Family

ID=77200870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544294A Pending JP2023514056A (ja) 2020-02-07 2021-02-05 免疫調節を使用した癌の治療レジメン

Country Status (4)

Country Link
US (1) US20230338402A1 (https=)
EP (1) EP4099994A4 (https=)
JP (1) JP2023514056A (https=)
WO (1) WO2021158884A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250179502A1 (en) * 2022-02-28 2025-06-05 University Of Massachusetts Targeting neuropilin 2 (nrp2) in lethal prostate cancer
WO2024073010A1 (en) * 2022-09-28 2024-04-04 University Of Cincinnati Inhibition of natural killer cell cytoxocity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521135A (ja) * 2015-07-16 2018-08-02 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
WO2020123496A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192158A (en) * 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521135A (ja) * 2015-07-16 2018-08-02 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
WO2020123496A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation

Also Published As

Publication number Publication date
EP4099994A4 (en) 2024-02-14
US20230338402A1 (en) 2023-10-26
WO2021158884A1 (en) 2021-08-12
EP4099994A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
US20250019388A1 (en) Stat3 degraders and uses thereof
US20230044943A1 (en) Pharmaceutical Combinations
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
JP2023514056A (ja) 免疫調節を使用した癌の治療レジメン
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
US20220257759A1 (en) Treatment of sarcoma using immunomodulation
TWI921668B (zh) Kras g12c抑制劑之給藥方案
WO2019129168A1 (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途
TW202612702A (zh) 吡啶并［２，３－ｄ］嘧啶－２（１Ｈ）－酮類衍生物聯合用藥在治療和預防腫瘤疾病中的用途
WO2025242031A1 (zh) 吡啶并[2,3-d]嘧啶-2(1H)-酮类衍生物联合用药在治疗和预防肿瘤疾病中的用途
AU2024357587A1 (en) Combination therapies for treating cancers
WO2025101427A1 (en) Use of an immunoconjugate for the treatment of endometrial cancer
WO2024258916A1 (en) Stat3 degraders and uses thereof
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
WO2025242190A1 (zh) 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
Johnson Phase II Study of Durvalumab (MEDI4736)(anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250611